Another biotech is in this space, which further validates TYP's endeavours in many respects
https://www.beckleypsytech.com/posts/beckley-psytech-announces-initial-results-from-phase-i-study-and-first-patients-dosed-in-phase-iia-study-of-ele-101-for-major-depressive-disorderA group of investors who research these things threw up a concern that Beckley's IP might overlap that of TYP.
So I contacted the CEO, Jason Carroll (who was most gracious and prompt with his response, given I'm not known for my medical knowledge!).
(I hope it's OK to mention this on a public forum ... if not the post may disappear)
Effectively Beckley is IV administered ...
ELE-101, is a proprietary intravenous formulation of psilocin currently being developed as a potential treatment for Major Depressive Disorder (MDD).TYP ... In TYP's case, the proprietary infusion delivery method is intended to provide a neuroplastic (psychedelic) state to patients via a continuous infusion of a stable (proprietary) form of psilocin over a 20 minute loading dose period, followed by a 2 hour maintenance period.
and Tryptamine Therapeutics holds a global PCT over the IV-infusion of both psilocybin & psilocin in addition to PCT's for the use of psilocybin (and its metabolites, including psilocin) in Binge Eating Disorder, Fibromyalgia & Irritable Bowel Syndrome.
PCT ... The Patent Cooperation Treaty (PCT) assists applicants in seeking patent protection internationally for their inventions, helps patent offices with their patent granting decisions, and facilitates public access to a wealth of technical information relating to those inventions.
By filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in alarge number of countries.
So ... this space is heating up! (And TYP is well positioned.)
